Dxcover Launches Brain Cancer Blood Test to Support Earlier Diagnosis
Dxcover, a global leader in AI-enabled diagnostics, has launched a brain cancer blood test in the UK following UKCA approval. Designed to help physicians detect tumors earlier, the test may also reduce ongoing imaging delays and support faster clinical decision-making across healthcare systems.
The clinically validated test delivers a 99.3% negative predictive value (NPV), enabling general practitioners (GPs) to reassure symptomatic patients sooner, make more informed imaging referrals, and accelerate diagnostic timelines. UK-based GPs and private specialists can now register their interest to access the test and integrate it into existing referral workflows.
Why the Brain Cancer Blood Test Matters for Patients
Detecting brain malignancies through a simple blood sample has long challenged researchers. Dxcover’s minimally invasive solution aims to overcome these barriers by improving diagnostic pathways and supporting better patient outcomes.
“To date, blood-based detection of brain malignancies has been out of reach due to technical challenges,” said Matthew J. Baker, CEO and co-founder of Dxcover.
Brain and central nervous system (CNS) tumors remain relatively rare, with approximately 300,000 new cases diagnosed globally each year according to the World Health Organization (WHO). Unfortunately, many cases are identified at advanced stages when treatment options are more limited.
Five-year survival rates are close to 33%, and research from Cancer Research UK suggests that reducing diagnosis time by just one month could lower mortality by 18–28%. Earlier detection tools may therefore play a critical role in improving survival and expanding treatment possibilities.
How the Brain Cancer Blood Test Supports Faster Referrals
Healthcare systems continue to face significant pressure on diagnostic imaging capacity. Patients experiencing neurological symptoms often wait weeks between their initial consultation, scan referral, imaging appointment, and final diagnosis.
The brain cancer blood test helps clinicians prioritize high-risk patients while allowing others to move forward in the diagnostic process with greater confidence. By supporting referral decisions, the test may improve patient triage and reduce unnecessary delays.
Liquid Biopsy Platform Delivers Results Within 24 Hours
Dxcover’s Liquid Biopsy Platform returns results in under 24 hours. For patients with positive findings, clinicians can escalate care quickly using evidence-based decision-making.
Specifically, the test helps doctors:
-
Prioritize urgent imaging requests
-
Justify specialist referrals
-
Align patients more quickly with secondary care pathways
Together, these capabilities could streamline clinical workflows and reduce diagnostic bottlenecks across healthcare providers.
A Step Forward for Early Brain Cancer Detection
The UK launch reflects growing momentum in AI-driven healthcare innovation. As minimally invasive technologies evolve, they are expected to reshape how serious diseases are detected and managed.
Earlier diagnosis can improve survival rates, speed treatment decisions, and strengthen patient confidence throughout the care journey. As adoption grows, the brain cancer blood test could become a critical tool in accelerating diagnosis and improving outcomes for patients worldwide.
